Nebivolol
- Generic Name
- Nebivolol
- Brand Names
- Bystolic
- Drug Type
- Small Molecule
- Chemical Formula
- C22H25F2NO4
- CAS Number
- 118457-14-0
- Unique Ingredient Identifier
- 030Y90569U
- Background
Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than atenolol, propranolol, or pindolol. Nebivolol and other beta blockers are generally not first l...
- Indication
Nebivolol is indicated to treat hypertension.
- Associated Conditions
- Hypertension
- Associated Therapies
- -
Nebivolol, Lifestyle Modification and Arterial Stiffness
- Conditions
- Interventions
- First Posted Date
- 2013-08-09
- Last Posted Date
- 2018-02-23
- Target Recruit Count
- 45
- Registration Number
- NCT01920282
Nebivolol Effects on Endothelial Function and Erectile Function
- First Posted Date
- 2013-06-25
- Last Posted Date
- 2013-06-25
- Lead Sponsor
- Martin M. Miner, MD
- Target Recruit Count
- 70
- Registration Number
- NCT01885988
- Locations
- 🇺🇸
University Medicine, Providence, Rhode Island, United States
🇺🇸Miriam Cardiology, Providence, Rhode Island, United States
🇺🇸The Miriam Hospital / The Men's Health Center, Providence, Rhode Island, United States
CPAP and Nebivolol in Hypertensive Obstructive Sleep Apnea (OSA) Patients.
- First Posted Date
- 2013-01-18
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Target Recruit Count
- 36
- Registration Number
- NCT01771406
- Locations
- 🇧🇪
University Hospitals Leuven, Leuven, Belgium
Economic Impact of Switching From Metoprolol to Nebivolol for Hypertension Treatment
- Conditions
- Interventions
- First Posted Date
- 2013-01-01
- Last Posted Date
- 2013-01-01
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 3000
- Registration Number
- NCT01758263
- Locations
- 🇺🇸
Forest Investigative Site 0, Jersey City, New Jersey, United States
The Effects of Nebivolol on the NO-system in Patients With Essential Hypertension
- First Posted Date
- 2012-09-06
- Last Posted Date
- 2014-03-04
- Lead Sponsor
- Erling Bjerregaard Pedersen
- Target Recruit Count
- 25
- Registration Number
- NCT01679652
- Locations
- 🇩🇰
Department of Medical Research, Holstebro Hospital, Holstebro, Denmark
Study to Evaluate Effect of Nebivolol on Angina in Women With Microvascular Disease
- First Posted Date
- 2012-08-15
- Last Posted Date
- 2017-04-20
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT01665508
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Nebivolol for the Prevention of Left Ventricular Systolic Dysfunction in Patients With Duchenne Muscular Dystrophy
- Conditions
- Interventions
- First Posted Date
- 2012-07-24
- Last Posted Date
- 2021-09-28
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 51
- Registration Number
- NCT01648634
- Locations
- 🇫🇷
Armand Trousseau Hospital, Paris, France
Can Nebivolol Reverse Inappropriate Left Ventricular Mass in Hypertensive Patients?
- First Posted Date
- 2012-05-24
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 1
- Registration Number
- NCT01605370
- Locations
- 🇺🇸
Mayo Clinic Arizona, Scottsdale, Arizona, United States
Nebivolol and Endothelial Regulation of Fibrinolysis (NERF)
- Conditions
- Interventions
- First Posted Date
- 2012-05-10
- Last Posted Date
- 2019-06-25
- Lead Sponsor
- University of Colorado, Boulder
- Target Recruit Count
- 44
- Registration Number
- NCT01595516
- Locations
- 🇺🇸
UC-Boulder Clinical and Translational Research Center, Boulder, Colorado, United States
A Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function
- First Posted Date
- 2012-02-01
- Last Posted Date
- 2020-07-17
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 76
- Registration Number
- NCT01522950
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.